Filgotinib
- Generic Name
- Filgotinib
- Brand Names
- Jyseleca
- Drug Type
- Small Molecule
- Chemical Formula
- C21H23N5O3S
- CAS Number
- 1206161-97-8
- Unique Ingredient Identifier
- 3XVL385Q0M
- Background
Rheumatoid arthritis (RA) is a chronic, autoimmune, systemic, and inflammatory disease that causes synovial joint symptoms and can limit range of motion in severe cases. The disease is associated with extra-articular manifestations, progressive disability, and comorbidities including cardiovascular disease and mental disorders. 50-70% of patients with RA are...
- Indication
Filgotinib is indicated for the treatment of active moderate to severe rheumatoid arthritis alone or in combination with methotrexate. Filgotinib is currently reserved for patients who are unable to tolerate or who have not responded adequately to one or more disease-modifying anti-rheumatic drugs (DMARDS).
...
- Associated Conditions
- Active, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Ulcerative Colitis
- Associated Therapies
- -
Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis
- First Posted Date
- 2021-05-04
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Alfasigma S.p.A.
- Target Recruit Count
- 1304
- Registration Number
- NCT04871919
- Locations
- 🇳🇱
READE, Amsterdam, Netherlands
🇩🇪Universitatsklinikum Dusseldorf, Düsseldorf, Germany
🇮🇹AOU Policlinico Vittorio Emanuele-PO San Marco, Catania, Italy
Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 27
- Registration Number
- NCT04608344
- Locations
- 🇺🇸
Prism Research, LLC, Saint Paul, Minnesota, United States
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug Therapy
- Conditions
- Interventions
- First Posted Date
- 2020-07-23
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT04483687
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drug Therapy
- Conditions
- Interventions
- First Posted Date
- 2020-07-23
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT04483700
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy
- Conditions
- Interventions
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 106
- Registration Number
- NCT04115839
- Locations
- 🇨🇦
G.R.M.O. (Groupe de recherche en maladies osseuses) Inc., Quebec, Canada
🇯🇵Keio University Hospital, Tokyo, Japan
🇵🇱Synexus Polska Sp. z o.o. Oddzial w Katowicach, Katowice, Poland
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy
- Conditions
- Interventions
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2022-05-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 67
- Registration Number
- NCT04115748
- Locations
- ðŸ‡ðŸ‡º
Synexus (DRS) - Synexus Magyarorszag Kft. Budapest, Budapest, Hungary
🇵🇱Centrum Medyczne Pratia Gdynia, Gdynia, Poland
🇵🇱Medycyna Kliniczna Marzena Waszczak-Jeka, Warszawa, Poland
Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis
- Conditions
- Interventions
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 109
- Registration Number
- NCT03926195
- Locations
- 🇧🇬
DCC 17 - Sofia EOOD, Sofia, Bulgaria
🇧🇬UMHAT Sv. Georgi, EAD, Plovdiv, Bulgaria
🇧🇬MHAT "Eurohospital" - Plovdiv, OOD, Plovdiv, Bulgaria
Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic Function
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2021-01-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 20
- Registration Number
- NCT03417778
- Locations
- 🇳🇿
Auckland Clinical Studies Ltd., Grafton, Auckland, New Zealand
🇺🇸Clinical Pharmacology of Miami, Miami, Florida, United States
🇩🇪APEX GmbH, Munich, Germany
An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis.
- First Posted Date
- 2017-10-25
- Last Posted Date
- 2022-04-21
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 122
- Registration Number
- NCT03320876
- Locations
- 🇧🇬
UMHAT "Kaspela", EOOD, Plovdiv, Bulgaria
🇧🇪ULB Hopital Erasme, Service de Rheumatology, Brussels, Belgium
🇧🇬UMHAT "SofiaMed", OOD, Block 1, Sofia, Bulgaria
Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)
- Conditions
- Interventions
- First Posted Date
- 2017-09-18
- Last Posted Date
- 2020-05-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 9
- Registration Number
- NCT03285711
- Locations
- 🇺🇸
University of Alabama at Birmingham (UAB), Birmingham, Alabama, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸University of Florida, Gainesville, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.